Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-440-9333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$250,000.00
Profitability
Miscellaneous
Employees73
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.15. View Intra-Cellular Therapies' Earnings History.
When is Intra-Cellular Therapies' next earnings date?
What price target have analysts set for ITCI?
7 equities research analysts have issued 1 year price objectives for Intra-Cellular Therapies' stock. Their predictions range from $16.00 to $31.00. On average, they expect Intra-Cellular Therapies' stock price to reach $25.14 in the next twelve months. This suggests a possible upside of 203.7% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.
What is the consensus analysts' recommendation for Intra-Cellular Therapies?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (10/15/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $26 price target on ITCI shares. Intra-Cellular reported 1Q19 financial performance, ending the period with cash of $312.8M. Our model projects sufficient funding into 2H20 and through several clinical and regulatory milestones including NDA acceptance/approval of lumateperone for schizophrenia and P3 data in bipolar depression (Studies 401 & 404) that are expected later this quarter. We also look forward to luma’s potential approval in 3Q19, the establishment of the company’s commercial team and its market launch as a differentiated, broadly active neuropsych product." (5/8/2019)
Has Intra-Cellular Therapies been receiving favorable news coverage?
News articles about ITCI stock have trended negative this week, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a news impact score of -2.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Intra-Cellular Therapies.
Are investors shorting Intra-Cellular Therapies?
Intra-Cellular Therapies saw a increase in short interest in September. As of September 30th, there was short interest totalling 8,900,000 shares, an increase of 43.5% from the August 30th total of 6,200,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 7.7 days. Approximately 19.2% of the shares of the company are sold short. View Intra-Cellular Therapies' Current Options Chain.
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH), Deciphera Pharmaceuticals (DCPH), Tricida (TCDA), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX), Alder Biopharmaceuticals (ALDR), Aimmune Therapeutics (AIMT), Insmed (INSM), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN) and Ironwood Pharmaceuticals (IRWD).
What other stocks do shareholders of Intra-Cellular Therapies own?
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
- Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)
- Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
- Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
- Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)
Who are Intra-Cellular Therapies' major shareholders?
Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.54%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Intra-Cellular Therapies stock include Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.
Which institutional investors are selling Intra-Cellular Therapies stock?
ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.
Which institutional investors are buying Intra-Cellular Therapies stock?
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $8.28.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $456.83 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.
What is Intra-Cellular Therapies' official website?
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]
MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
